FDA Inspections
FDA Non-Baseline Surveillance Inspection
A non-baseline surveillance inspection is a routine FDA inspection with a narrower footprint than a baseline. The investigator still starts from your risk management documentation, but concentrates on the areas your risk picture, products and history point to.
At a Glance
- Conducted by
- FDA investigators
- Notice
- Usually pre-announced about five days ahead; begins with Form 482
- Framework
- Compliance Program 7382.850 and the QMSR
- Scope
- Focused coverage of selected QMS areas, chosen on risk
- Possible outcome
- Observations on Form 483; NAI, VAI or OAI classification
What It Is
Compliance Program 7382.850 lists non-baseline surveillance as its own inspection type, alongside baseline, for-cause, compliance follow-up and PMA pre-approval or postmarket inspections. It is still surveillance, meaning it isn't prompted by a specific problem, but it doesn't attempt the broad sweep of a baseline inspection.
The practical difference is depth versus breadth. The investigator picks a subset of the six QMS areas and the four other FDA requirements and goes deep on them, guided by your risk management documentation and the risk profile of your devices and processes. You won't know in advance which areas those are.
Because the scope is narrower, each sampled record carries more weight. One weak CAPA or an unexplained change can define the inspection in a way it might not in a broader review.
Who Conducts It
FDA investigators conduct it, usually after calling ahead about five days before for a domestic site, opening with a Form 482. The investigator can narrow or widen the focus as the inspection goes, depending on what the records show.
Your team runs the same structure as for any FDA inspection: a host who controls the flow, a scribe, a back room for retrieval and review, and process owners ready for sustained questioning in whichever areas get picked.
What Triggers It
- FDA's routine, risk-based surveillance planning
- Device and process characteristics in your risk file that make certain QMS areas the obvious place to look
- Your inspection history and what earlier inspections covered
- Changes since the last inspection that FDA may want to examine, such as new products, suppliers or manufacturing processes
What They Look At
Risk Management Documentation
The entry point. Investigators use it to choose where to go deep, so its accuracy shapes where the rest of the inspection lands.
High-Risk Processes
Special processes such as sterilization, sealing, cleaning or software-controlled production, where validation and ongoing monitoring carry the most weight.
Recent Changes
Design, process, supplier and labeling changes since the last inspection, and whether each was assessed for risk, validated where needed and approved.
CAPA and Complaint Trends
Whether data analysis catches recurring problems and whether CAPAs actually fix them, with effectiveness evidence to show it.
Postmarket Requirements
MDR decisions, corrections and removals, tracking and UDI, any of which may be sampled on its own.
Records Behind the Procedures
With fewer areas in scope, the investigator can pull more records per area, so thin evidence behind a sound procedure stands out.
How to Prepare
- 01
Rank Your Areas by Risk
Use your own risk file to predict where an investigator would look first, then strengthen those areas before the rest.
- 02
Deep-Sample Your Own Records
Pull several complete record sets for each high-risk process, the way a focused inspection would, and read them end to end.
- 03
Walk Every Recent Change
For each change since the last inspection, confirm that the risk assessment, validation, approvals and training records exist and agree with each other.
- 04
Prepare Experts for Depth
In a focused inspection the same expert may be questioned for a long stretch. Practice the third and fourth follow-up question, not just the opener.
- 05
Keep the Whole System Ready
Focused doesn't mean predictable. The investigator can widen scope, so don't neglect the areas you assume are safe.
Common Pitfalls
- Assuming a focused inspection is a light one and preparing less.
- Guessing the scope, leaving other areas untouched, then watching the investigator widen the inspection.
- Validation reports that exist but don't match current process parameters, equipment or software versions.
- Change records that skip the risk assessment because the change seemed minor.
- Experts who handle the first question well but drift when the investigator follows up for detail.
How QMSAdvisor Helps
- A risk-ranked gap analysis that points at the QMS areas a focused inspection is most likely to sample, reviewed by an advisor before you see it.
- Deep-sample checks of record sets for your highest-risk processes, with findings that cite the exact document and location.
- FDA Inspection Simulator sessions scoped to selected CP 7382.850 areas, so experts practice sustained questioning on their own process.
- An action plan that strengthens the likeliest areas first without leaving the rest behind.
FDA Inspection Readiness (CP 7382.850)
FDA device inspection preparation built around Compliance Program 7382.850 and its risk-based approach.
Mock FDA Inspection
A practice FDA inspection in our Inspection Simulator, with an advisor playing the investigator.
Full Audit Readiness Assessment
Documents, records, evidence and interviews, checked against the specific audit you're facing next.
Standards and Regulations Involved
Questions About the FDA Non-Baseline Surveillance Inspection
How does FDA choose which areas to cover?
The program is risk-based and starts from your risk management documentation, so your risk file, products and history shape the focus. FDA doesn't announce the areas in advance, and the investigator can adjust as the inspection proceeds.
Is a non-baseline inspection less serious than a baseline?
It covers less ground, but the possible outcomes are the same: Form 483 observations and an NAI, VAI or OAI classification. A focused inspection can still be classified OAI if it finds significant problems.
Can a non-baseline inspection turn into something broader?
The investigator follows the evidence. If records in one area point to problems elsewhere, expect the questions to follow them. Prepare the whole system, not just the areas you expect.
How should we prepare if we don't know the inspection type?
Prepare for the broadest case, then rehearse depth in your highest-risk processes. That covers both a baseline sweep and a focused deep dive.
Related Audits and Inspections
FDA Baseline Surveillance Inspection
FDA's comprehensive surveillance inspection of your quality system under Compliance Program 7382.850.
FDA For-Cause Inspection
An FDA inspection prompted by specific information, such as complaints, MDRs or recalls, and focused on it.
Mock Audit and Mock Inspection
A realistic practice inspection, with an advisor playing the FDA investigator, before the real one arrives.
Request an Assessment
Prepare for Your FDA Non-Baseline Surveillance Inspection With an Advisor
Tell us what's coming and when, and an advisor will scope readiness work around it. Please don't send confidential documents yet: secure upload is set up after onboarding.
